🇺🇸 FDA

Drug profile · INN

trastuzumab and hyaluronidase-oysk

HERCEPTIN HYLECTA

approved
US status
approved
Patents linked
0
News articles
0

Quick answer

trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN trastuzumab and hyaluronidase-oysk
Brand HERCEPTIN HYLECTA
Route SUBCUTANEOUS
Formulation INJECTABLE

Frequently asked questions

What is trastuzumab and hyaluronidase-oysk?

trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for trastuzumab and hyaluronidase-oysk?

HERCEPTIN HYLECTA is a marketed brand name for trastuzumab and hyaluronidase-oysk. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of trastuzumab and hyaluronidase-oysk?

trastuzumab and hyaluronidase-oysk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.